Table 2.

European Randomized Study of Screening for Prostate Cancer (ERSPC) Screening Group Methodology and Outcomes

Positive PSA tests	20,437 (16.2%)
Biopsies	17,543
Biopsy compliance	85.8%
False positive (biopsy after elevated PSA)	13,308 (75.9%)
Men needed to screen to prevent 1 death	1410*
(adjusting for noncompliance)	1068
Men needed to be treated to prevent 1 death	48

^*95% confidence interval, 1142–1721.

PSA, prostate-specific antigen.

Data from Schröder FH et al.¹